A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

ClinicalTrials.gov ID: NCT04830137

Public ClinicalTrials.gov record NCT04830137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Study identification

NCT ID: NCT04830137
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Enrollment: 248 participants

Conditions and interventions

Conditions

Interventions

NX-2127 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 4, 2021
Primary completion: Apr 30, 2026
Completion: Apr 30, 2027
Last update posted: Mar 19, 2026

2021 – 2027

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 16

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
University of California Irvine	Orange	California	92868	Completed
University of California San Francisco Medical Center	San Francisco	California	94143	Completed
Sarah Cannon Research Institute at Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Mount Sinai Comprehensive Cancer Center	Miami Beach	Florida	33140	Completed
Sarah Cannon Research Institute at Florida Cancer Specialists	Sarasota	Florida	34203	Completed
The University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
National Institutes of Health Clinical Center	Bethesda	Maryland	20814	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Completed
University of Cincinnati Medical Center	Cincinnati	Ohio	45267	Completed
OSU Wexner Medical Center	Columbus	Ohio	43210	Completed
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
Baylor University Medical Center	Dallas	Texas	75246	Completed
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute, University of Utah	Salt Lake City	Utah	84112	Recruiting
Swedish Cancer Institute	Seattle	Washington	98104	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04830137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 19, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04830137 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →